MaxCyte Inc (LON:MXCT) has said its subsidiary, CARMA Cell Therapies, will share the results of a detailed phenotypic and functional characterisation of MCY-M11, its lead anti-mesothelin CAR-PBMC cell therapy candidate, at the Society for Immunotherapy of Cancer's (SITC) 35th anniversary meeting.
The life sciences company said the Virtual Scientific Program will begin on Monday and run through to November 14, with the ePoster entitled “MCY-M11, a CAR-PBMC cell product transiently expressing a mesothelin targeted mRNA CAR, exhibits desirable functional and immune phenotype attributed to sustained antitumor immunity in vitro," to be presented during SITC's Poster Symposium with a live Q&A on November 12 from 4:50-5:20pm eastern time and on Saturday, November 14 from 1:00-1:30pm EST.
MCY-M11 is a wholly-owned, non-viral, mRNA-based cell therapy candidate manufactured using unstimulated peripheral blood mononuclear cells (PBMCs) and is currently under Phase I clinical evaluation for the treatment of advanced ovarian cancer and malignant peritoneal mesothelioma, a type of cancer that forms in the lining of the abdomen and is often caused by asbestos fibres.
"We are encouraged by these in vitro findings, which demonstrate MCY-M11's potential to enable a long-term antitumor response. This work brings us one step closer to understanding the mechanism of action of MCY-M11 and provides strong non-clinical rationale for its use as a cancer cell therapy", CARMA’s vice-president of non-clinical and translational studies Dhana Chinnasamy said in a statement.
Shares in MaxCyte were 1.4% higher at 441p in mid-afternoon trading on Monday.